健帆生物(300529.SZ)簽訂醫療器械產業(血液淨化)項目投資合作協議
格隆匯3月5日丨健帆生物(300529.SZ)公佈，2020年3月5日，公司與珠海(國家)高新技術產業開發區管理委員會簽訂了《健帆集團醫療器械產業(血液淨化)項目投資合作協議》，擬在珠海高新區唐家灣主園區投資建設健帆集團醫療器械產業(血液淨化)項目，投資總金額約15億元。
項目內容：為進一步擴充現有血液灌流器產能，並豐富整體血液淨化產品線，乙方擬在珠海高新區唐家灣主園區投資健帆集團醫療器械產業(血液淨化)項目，建設集血液灌流器、醫用納米級膜材料的血液透析器及血漿分離器、血液淨化管路、血液淨化整機設備及醫用縫合線等醫療器械產品為一體的產業園區。主要計劃建設內容包括：血液灌流器、血液透析器、血漿分離器、血液淨化管路及醫用縫合線生產線、血液淨化整機設備生產車間、其他配套生活設施(員工宿舍樓)及其他必要的倉庫、能源、環保、水處理系統、道路、管網建設等。該協議項目投資總額約15億元，包含固定資產投資約12億元、鋪底流動資金及其他資金，主要投入包括但不限於土地購置、建築安裝工程、廠房裝修及研發生產設備購置等。
該協議項目預期產出效益情況如下：項目建成並投產後當年產值不低於2.4億元，投產後第二年產值不低於4.8億元，投產後第三年產值不低於7.2億元，投產後第四年產值不低於9.6億元，投產後第五年(達產年)產值不低於12億元。
隨着血液淨化行業的迅速發展，市場對血液淨化產品種類、產品質量和安全性等方面提出了更高的要求。為更好的滿足市場需求，進一步提升公司現有血液灌流器產能，並豐富整體血液淨化產品線，進一步提升公司在血液淨化領域的整體技術實力和產品市場競爭力，公司擬在珠海高新區投資建設國內規模領先、自動化程度高的血液淨化設備及耗材生產基地，以更好地滿足廣大醫護和患者的需求，創造豐厚的社會效益和經濟效益。
公司此次在珠海高新區唐家灣金鼎工業園投資建設血液淨化項目，是在現有的珠海總部健帆園(南北兩區)、湖北黃岡、天津血液淨化三大生產基地基礎上的又一次產能擴充，有利於完善公司華南、華中、華北的產業戰略佈局，形成以珠海基地為主體、以黃岡天津基地為雙翼、輻射全國的產能戰略佈局，為公司未來的持續快速發展奠定堅實的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
